Physician profile
Edward S Thomas
NPI 1154327245
$15,261.64
in general payments reported to CMS, 2019-2025
37 companies · $2,431 in 2025
The $2,431 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $1,400 · 2021: $2,321 · 2022: $2,079 · 2023: $2,434 · 2024: $2,224 · 2025: $2,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,000 · Education: $88.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,000.43 |
| Education | $88.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,234.07 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,454.63 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,431.99 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,116.26 | 2019-2025 | Farxiga, Andexxa |
| Medtronic, INC. | $1,071.49 | 2021-2025 | Abre, Micra, Cobalt Dr Mri Surescan |
| Shockwave Medical, INC | $1,061.77 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $1,016.57 | 2019-2025 | |
| Amgen INC. | $966.28 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $807.95 | 2021-2025 | Verquvo |
| Pfizer INC. | $760.25 | 2019-2025 | |
| Medtronic Vascular, INC. | $525.10 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $272.87 | 2024-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $235.32 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $220.48 | 2025 | Onpattro, Amvuttra |
| Amarin Pharma, INC. | $210.11 | 2020-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.